Pharmaceutical Microbiology Market Analysis

Product Type (Pharmaceutical, Biopharmaceutical)

In pharmaceutical microbiology market, biopharmaceutical segment is likely to capture over 54% share by 2036. Biopharmaceuticals have a high therapeutic value and can successfully treat a wide range of chronic ailments, such as cancer, diabetes, cardiovascular disease, Parkinson's disease, and many more since they are produced utilizing living bacteria and animal cells. Furthermore, it is anticipated that the need for biologic pharmaceuticals would increase as the global population ages and becomes more vulnerable to chronic disorders.

Pharmaceutical companies are also making significant investments in the development of biological medications, which is creating a growing pipeline of cutting-edge treatments that address a range of illnesses. For example, Novartis's Cosentyx® (secukinumab) has been licensed by the US Food and Drug Administration (FDA) to treat people with moderate to severe hidradenitis suppurative (HS). Cosentyx.2 is the sole FDA-licensed completely human biopharmaceutical that directly suppresses interleukin-17A (IL-17A), a cytokine believed to be involved in HS inflammation.

Service (Microbial Identification, Antimicrobial Effectiveness, Stability Studies, Validation of Microbial Recovery, Minimum Inhibitory Concentration (MIC) Evaluations, Minimum Bactericidal Concentration (MBC) Evaluations)

In pharmaceutical microbiology market, microbial identification segment is predicted to hold more than 35% revenue share by 2036. With the expanding complexity of pharmaceutical manufacturing processes and the worldwide nature of supply chains, pharmaceutical companies are increasingly concerned about microbial contamination. As a result, there is a growing emphasis on microbiological identification to detect and treat contamination issues promptly, ensuring product quality and safety. Furthermore, technological advancements have resulted in the development and acceptance of rapid microbiological techniques (RMM) for microbial identification, which is expected to rise further in the future.

Also, the advent of new microbial diseases is also propelling the growth of the segment. Some microbial diseases include tuberculosis, Lyme disease, measles, malaria, fungal diseases, and others. According to the most recent estimates, there are 476,000 new Lyme cases in the United States each year, and is expected to increase by 59% by 2021. Scientists predict that two million people will suffer from post-treatment Lyme disease by the end of 2020. Microbial identification is critical for tracking and characterizing these infections to establish effective control measures and treatment plans.

Our in-depth analysis of the global market includes the following segments: